Evidence Grade A — Regulatory approved. 20 published studies. 85 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Lutetium Lu-177 dotatate (sold as Lutathera) is a targeted radiation treatment for neuroendocrine tumours — rare cancers, often found in the digestive system, that display specific receptors on their surface. It works like a guided missile: a tumour-seeking peptide carries a radioactive atom directly to the cancer cells, destroying them from within while largely sparing surrounding tissue. It is given as four intravenous infusions, eight weeks apart.
Lutetium Lu-177 Dotatate is also known by these brand and alternate names:
20 published studies: 10 human, 0 animal, 0 in-vitro, 6 reviews
Lutathera is marketed by Novartis (approved January 2018) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. It is administered as four intravenous infusions given every 8 weeks.
The NETTER-1 trial showed dramatic results: at 20 months, 65% of patients on Lutathera had not progressed compared to only 11% on high-dose octreotide alone. Patients must have somatostatin receptor-positive tumours confirmed by nuclear imaging before treatment. The main risks are bone marrow suppression (affecting blood cell production) and kidney toxicity. Lutathera established peptide receptor radionuclide therapy as a mainstream cancer treatment approach and paved the way for similar radiopharmaceuticals in other cancers.
Neuroendocrine tumour cells abundantly display somatostatin receptors on their surface. Lutathera consists of a somatostatin-like peptide (that finds and binds to these receptors) attached via a chemical linker to a radioactive atom (lutetium-177). Once the peptide docks onto the tumour cell's receptor, the whole complex is pulled inside the cell. The lutetium-177 then emits beta radiation that damages the tumour cell's DNA, causing it to die. The radiation penetrates only about 2mm of tissue, limiting collateral damage to surrounding healthy tissue.
The NETTER-1 trial showed dramatic results: at 20 months, 65% of patients on Lutathera had not progressed compared to only 11% on high-dose octreotide alone. This established peptide receptor radionuclide therapy as a mainstream cancer treatment and paved the way for similar radiopharmaceuticals targeting other cancers. Patients must have their tumours confirmed as somatostatin receptor-positive by a nuclear imaging scan before treatment. The main risks are bone marrow suppression (affecting blood cell production) and kidney toxicity, and there is a small long-term risk (approximately 2%) of secondary blood cancers (MDS/AML). A follow-up trial (NETTER-2) has evaluated use earlier in the treatment course with positive results, and combination approaches with other cancer drugs are in active study.
PeptideTrace tracks 85 registered clinical trials for Lutetium Lu-177 Dotatate sourced from ClinicalTrials.gov.
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 10
FDA SUPPL 1
FDA SUPPL 20
FDA SUPPL 19
FDA SUPPL 23
FDA SUPPL 26
FDA SUPPL 31
FDA SUPPL 32
Lutetium Lu-177 dotatate is a radiolabeled somatostatin analogue: [DOTA0,Tyr3]-octreotate (8-AA cyclic octapeptide) conjugated to DOTA chelator and radiolabeled with Lu-177 (beta emitter, half-life 6.647 days). Peptide-DOTA MW ~1,365 Da. Tyr3 enhances SSTR2 affinity, DOTA provides stable chelation. IV 7.4 GBq q8w x4 doses with amino acid renal protection.
Binds SSTR2 (Kd ~1 nM) overexpressed on well-differentiated NET cells. After receptor-mediated internalization, Lu-177 delivers targeted beta-radiation (max tissue penetration ~2 mm) causing DNA double-strand breaks, cell cycle arrest, and apoptosis. Limited penetration minimizes normal tissue damage while crossfire effect irradiates SSTR2-negative neighbors. This is peptide receptor radionuclide therapy (PRRT).
Marketed as Lutathera. Approved January 26, 2018. NETTER-1 (N=229): PFS at 20 months 65.2% vs. 10.8% vs. octreotide LAR 60 mg (HR 0.18, P<0.0001). ORR 18% vs. 3%. OS trend HR 0.40. Indication: SSTR-positive GEP-NETs in adults.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
Evidence Reviews
Regulatory Status
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
